News

Zydus Lifesciences Limited announced the completion of its acquisition of the API business of Sterling Biotech Limited, following the fulfillment of conditions precedent and closing date adjustments as outlined in the Business Transfer Agreement dated September 17, 2024.

Zydus Lifesciences Limited will hold a meeting of its Board of Directors on Wednesday, November 4, 2026, to approve unaudited financial results for the quarter and half year ended September 30, 2026, according to a regulatory filing. The trading window for the company`s directors and designated persons will be closed until Friday, November 6, 2026, and will reopen on Monday, November 9, 2026.

Zydus Lifesciences Limited confirmed that certificates of equity shares received for dematerialization during the quarter ended September 30, 2026, have been mutilated and cancelled after due verification, according to a regulatory filing with the BSE Limited and the National Stock Exchange of India Limited. The confirmation was based on a certificate received from MUFG Intime India Private Limited, formerly known as Link Intime India Private Limited, which also confirmed that the securities were accepted or rejected by the depositories and listed on the stock exchanges.

Zydus Lifesciences Limited will close its trading window for directors and designated persons and their immediate relatives from October 1, 2026, until 48 hours after the declaration of unaudited financial results for the quarter and half year ending September 30, 2026, as stated in a filing with the BSE Limited and National Stock Exchange of India Limited.

Zydus Lifesciences Ltd share price gained 0.49% to Rs 1120.7 after the company`s net profit tanked by 28.99% to Rs 952.4 crore, while revenue from operations slightly gained 4.94% to Rs 7802.0 crore in Q2FY26 over Q1FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 24.56 lakh crore, gaining 4.63%. It has marginally improved by 0.56% over last one week and climbed by 13.27% in last one month while the market capitalization of Zydus Lifesciences Ltd has inched up 0.20% and 18.32% in the same period respectively. Profit before tax (PBT) of Zydus Lifesciences Ltd stood at Rs 1306.6 crore in Q2 FY26, plunging by 31.97% year-on-year, and tumbling by 21.27% quarter-on-quarter. EBITDA came in at Rs 1823 crore, slipping 5.70% YoY and nosediving by 24.66% sequentially. Total expenses rose by 19.88% to Rs 6642.3 crore in Q2FY26 over Q2FY25. During the quarter, cost of materials consumed stood at Rs 1251.2 crore, marginally falling by 7.13% YoY, while employee benefits expense was at Rs 1368.2 crore, rising by 10.45% YoY. For the TTM ended FY26, revenue from operations grew 18.37% to Rs 26719.7 crore, while net profit grew slightly 8.92% to Rs 5026.4 crore, compared to previous TTM. EBITDA witnessed a strong improvement of 728020% to Rs 7965.6 crore, and PBT saw a minor gain of 9.86% to Rs 6621.1 crore compared to previous TTM. The company`s consolidated net cash flow from operating activities stood at Rs 2116.6 crore in FY26, as against Rs 6781.1 crore in FY25. Zydus Lifesciences Ltd surged by 17.29% in last one year, significantly outperforming the benchmark BSE Sensex which has eased by 2.56% during the same period.